Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to 25.59%.

  • Macrogenics' EBIT Margin fell 233600.0% to 25.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 76.6%, marking a year-over-year increase of 34200.0%. This contributed to the annual value of 73.74% for FY2024, which is 2126400.0% up from last year.
  • Latest data reveals that Macrogenics reported EBIT Margin of 25.59% as of Q3 2025, which was down 233600.0% from 165.27% recorded in Q2 2025.
  • Macrogenics' EBIT Margin's 5-year high stood at 48.95% during Q3 2024, with a 5-year trough of 1763.06% in Q2 2024.
  • For the 5-year period, Macrogenics' EBIT Margin averaged around 325.77%, with its median value being 303.85% (2021).
  • As far as peak fluctuations go, Macrogenics' EBIT Margin plummeted by -14207800bps in 2024, and later soared by 15977900bps in 2025.
  • Over the past 5 years, Macrogenics' EBIT Margin (Quarter) stood at 411.65% in 2021, then skyrocketed by 104bps to 16.39% in 2022, then tumbled by -2908bps to 460.39% in 2023, then skyrocketed by 71bps to 132.09% in 2024, then skyrocketed by 119bps to 25.59% in 2025.
  • Its EBIT Margin stands at 25.59% for Q3 2025, versus 165.27% for Q2 2025 and 323.1% for Q1 2025.